BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15273706)

  • 21. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised study of 10 microg/kg/day (single dose) vs 2 x 5 microg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients.
    Carrión R; Serrano D; Gómez-Pineda A; Díez-Martín JL
    Bone Marrow Transplant; 2003 Sep; 32(6):563-7. PubMed ID: 12953127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
    Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
    Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenograstim administration to HLA-identical donor-recipient pairs to accelerate marrow recovery post-transplant.
    Atkinson K; Fay K; Nivison-Smith I; Downs K
    Bone Marrow Transplant; 1997 Jan; 19(1):15-21. PubMed ID: 9012926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients.
    Majado MJ; Minguela A; González-García C; Salido E; Blanquer M; Funes C; Insausti CL; García-Hernández AM; Moraleda JM; Morales A
    J Clin Apher; 2009; 24(1):12-7. PubMed ID: 19170164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization.
    Romeo A; Chierichini A; Spagnoli A; Vittori M; Vacca M; Gozzer M; Spadea A; Anaclerico B; Dessanti ML; D'Andrea M; Toglia G; Annino L; Petti MC; Mengarelli A; Arcese W;
    Transfusion; 2010 Nov; 50(11):2432-46. PubMed ID: 20553434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue.
    Nolan L; Lorigan P; Chilton S; Newman J; Else R; Smith P; Linch D; Sweetenham JW; Johnson PW
    Br J Haematol; 2007 Jun; 137(5):436-42. PubMed ID: 17433027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F; Cavenaghi L; de Melo CM
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Peripheral blood stem cell collection in pediatric malignancies: comparison between three mobilizing regimens].
    De Pasquale MD; Cacchione A; Foco M; Gozzer M; Libera F; Soscia F; Ragni G; Cappelli C
    Clin Ter; 2003; 154(5):305-9. PubMed ID: 14994920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
    Kim IH; Park SK; Suh OK; Oh JM
    Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment.
    Milone G; Leotta S; Indelicato F; Mercurio S; Moschetti G; Di Raimondo F; Tornello A; Consoli U; Guido G; Giustolisi R
    Bone Marrow Transplant; 2003 May; 31(9):747-54. PubMed ID: 12732880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
    Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG
    Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Kim S; Kim HJ; Park JS; Lee J; Chi HS; Park CJ; Huh J; Suh C
    Ann Hematol; 2005 Oct; 84(11):742-7. PubMed ID: 16132903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
    Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used.
    Ings SJ; Balsa C; Leverett D; Mackinnon S; Linch DC; Watts MJ
    Br J Haematol; 2006 Sep; 134(5):517-25. PubMed ID: 17018030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral blood stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute and old myocardial infarction for intracoronary cell infusion.
    Chang SA; Kang HJ; Lee HY; Kim KH; Hur J; Han KS; Park YB; Kim HS
    Heart; 2009 Aug; 95(16):1326-30. PubMed ID: 19460773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.